How Drug Control Policy and Practice Undermine Access to Controlled Medicines
Open Access
- 1 June 2017
- journal article
- Vol. 19 (1), 237-252
Abstract
Drug conventions serve as the cornerstone for domestic drug laws and impose a dual obligation upon states to prevent the misuse of controlled substances while ensuring their adequate availability for medical and scientific purposes. Despite the mandate that these obligations be enforced equally, the dominant paradigm enshrined in the drug conventions is an enforcement-heavy criminal justice response to controlled substances that prohibits and penalizes their misuse. Prioritizing restrictive control is to the detriment of ensuring adequate availability of and access to controlled medicines, thereby violating the rights of people who need them. This paper argues that the drug conventions’ prioritization of criminal justice measures—including efforts to prevent non-medical use of controlled substances—undermines access to medicines and infringes upon the right to health and the right to enjoy the benefits of scientific progress. While the effects of criminalization under drug policy limit the right to health in multiple ways, we draw on research and documented examples to highlight the impact of drug control and criminalization on access to medicines. The prioritization and protection of human rights—specifically the right to health and the right to enjoy the benefits of scientific progress—are critical to rebalancing drug policy.Keywords
This publication has 31 references indexed in Scilit:
- Do more robust prescription drug monitoring programs reduce prescription opioid overdose?Addiction, 2017
- Reasons for drug policy reform: prohibition enables systemic human rights abuses and undermines public healthBMJ, 2017
- European rating of drug harmsJournal of Psychopharmacology, 2015
- Access to controlled medicines for palliative care in India: gains and challenges.Indian Journal of Medical Ethics, 2015
- Effects of Schedule I drug laws on neuroscience research and treatment innovationNature Reviews Neuroscience, 2013
- Modernizing methodology for the WHO assessment of substances for the international drug control conventionsDrug and Alcohol Dependence, 2013
- Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) EnantiomersIn Vitroand in the MPTP-Lesioned Primate:R-MDMA Reduces Severity of Dyskinesia, WhereasS-MDMA Extends Duration of ON-TimeJournal of Neuroscience, 2011
- Concerns about injectable naltrexone for opioid dependenceThe Lancet, 2011
- Drug harms in the UK: a multicriteria decision analysisThe Lancet, 2010
- Vladimir Mendelevich: fighting for drug substitution treatmentThe Lancet, 2006